Updated
Updated · Yahoo Finance · Aug 22
Tempus AI Director Nadja West Sells 3,000 Shares for $161,700 Under 10b5-1 Plan
Updated
Updated · Yahoo Finance · Aug 22

Tempus AI Director Nadja West Sells 3,000 Shares for $161,700 Under 10b5-1 Plan

1 articles · Updated · Yahoo Finance · Aug 22

Summary

  • Nadja West sold 3,000 Tempus AI Class A shares on Aug. 14 at a weighted average $53.90, according to an SEC Form 4 filing, for total proceeds of $161,700.
  • The sale was executed under a Rule 10b5-1 trading plan West adopted on May 15, a preset arrangement used to schedule insider sales and reduce concerns about material non-public information.
  • West still directly holds 34,981 shares after the transaction, a stake valued at about $1.8 million based on the Aug. 14 closing price of $52.10.
  • Tempus AI, a Chicago-based healthcare technology company, reported $1.4 billion in trailing-12-month revenue but a net loss of $254.4 million; its market capitalization was about $9.0 billion.

Insights

Despite strong 2026 revenue growth, why are Tempus AI insiders collectively scheduling stock sales amid elevated short interest?
Does the recent FDA approval for Tempus AI's diagnostic test justify its volatile valuation despite ongoing unprofitability?
How will Tempus AI leverage its massive 500-petabyte clinical dataset to overcome its substantial net losses and high debt?